NCT04165096 · Interventional trial
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
Overall registry status Completed
Phase 2
Conditions Carcinoma, Non-Small-Cell Lung
Delaware Valley sites
- Abramson Cancer Center of the University of Pennsylvania ( Site 0010) · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory